O verexpression of interleukin (IL)-13 in the murine lung causes eosinophil-predominant and macrophage-predominant inflammation, increased airway resistance, and airway hyperresponsiveness. 1 These mice also manifest increased production and accumulation of surfactant apoproteins and alterations in surfactant phospholipid composition. 2 However, the effects of IL-13 on surfactant function have not been defined. We hypothesized that IL-13 alters surfactant function as well as production.
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Abbreviations: G ϭ phosphatidylglycerol; sPLA 2 ϭ secretory phospholipase A 2 W e have reported that secretory phospholipase A 2 (sPLA 2 ) enzymes are elevated in the BAL fluid of asthmatic patients following inhaled allergen challenges, but the sources and functional impact of the sPLA 2 enzymes are unknown. Eosinophils infiltrate lung mucosa during allergic asthma episodes, and eosinophils secrete inflammatory proteins, including sPLA 2 . We and others have found that eosinophils contain 14-fold to 50-fold more sPLA 2 protein than neutrophils. We found that eosinophils secrete sPLA 2 in vitro rapidly (peak in 2 min), while neutrophil secretion of similar enzymatic activity is continuous for Ͼ 15 min. We have now specifically identified the group IID messenger RNA, isolated from peripheral blood eosinophils using reverse-transcriptase polymerase chain reaction.
The complementary DNA was sequenced and was confirmed as the group IID gene product. The preliminary real-time polymerase chain reaction data indicate that the IID sPLA 2 in eosinophils is increased by interleukin-5. In situ hybridization using the cloned complementary DNA showed that airway epithelial cells and infiltrating eosinophils (in nasal polyps) express the IID sPLA 2 messenger RNA.
Studies of surfactant function, by others and by us, have found that surfactant from the BAL fluid of challenged asthmatic patients is dysfunctional relative to surfactant from healthy control subjects or from asthmatic patients prior to allergen challenge. Recombinant group IID sPLA 2 caused surfactant dysfunction. The group IID has specificity for phosphatidylglycerol (PG) (rather than phosphatidylcholine). Although phosphatidylcholine is the predominant phospholipid in surfactant, the group IID sPLA 2 potently induced surfactant dysfunction in vitro, and that dysfunction paralleled hydrolysis of the PG component in the surfactant. Thus, eosinophils may contribute to surfactant dysfunction in asthma patients by causing hydrolysis of the PG component of the surfactant. 
Modulation of Vasodilator-

T
he attachment and migration of airway epithelial cells is an important aspect of the repair of antigen-induced inflammatory injury in patients with asthma. Cytoskeletal reorganization is required for the altered attachment and migration of epithelial cells. Vasodilator-stimulated phosphoprotein (VASP) mediates focal adhesion and actin filament binding in a variety of cells and acts as an inhibitor of cell movement. Phosphorylation of VASP via cyclic adenosine monophosphate-dependent and cyclic guanosine monophosphate-dependent protein kinases releases this "brake" on cell motility.
Segmental allergen (Ag) challenge increases phosphorylation of VASP in the airway epithelium. In addition, ␤ 2 -agonist use increases epithelial VASP phosphorylation and, thereby, alters cell adhesion and motility.
Materials and Methods
Brush biopsy specimens from the human bronchial epithelium from asthmatic subjects were obtained in the following two separate protocols: (1) before (day 1) and after segmental allergen challenges (days 2, 9, and 16) in a recovery-from-injury protocol (nine patients); and (2) before (day 1) and 24 h after segmental allergen challenge (day 2) at baseline, after a 2-week period of regular therapy with an inhaled ␤ 2 -agonist agent or placebo, and after 1 additional week of withdrawal from therapy with a ␤ 2 -agonist agent or placebo (five patients [two patients receiving ␤ 2 -agonist agent and three patients receiving placebo]). Cell lysates were assessed for VASP (46 kd) and phosphorylation of VASP (50 kd) by Western blot analyses.
